Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 13/20 | 1.00 |
| ▸ | DNMT3A | Q9Y6K1 | 9/20 | 1.00 |
| ▸ | DNMT3L | Q9UJW3 | 6/20 | 1.00 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 1.00 |
| ▸ | MYC | P01106 | 1/20 | 1.00 |
| ▸ | MAP2K3 | P46734 | 1/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786360 | 1.00 | DNMT1 (1.00) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| SCHEMBL29351315 | 1.00 | DNMT1 (1.00) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| Hydrochloric Acid SCHEMBL1886043 | 0.99 | DNMT1 (0.98) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| Hydrochloric Acid SCHEMBL1880676 | 0.99 | DNMT1 (0.98) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| SCHEMBL3657042 | 0.94 | DNMT1 (1.00) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| Hydrochloric Acid SCHEMBL1880578 | 0.94 | DNMT1 (0.98) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| SCHEMBL3789536 | 0.93 | DNMT1 (1.00) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| SCHEMBL3800388 | 0.92 | DNMT1 (0.85) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| SCHEMBL3784380 | 0.92 | DNMT1 (0.85) | DNMT1DNMT3ADNMT3LEHMT1MYC | |
| Hydrochloric Acid SCHEMBL1878590 | 0.92 | DNMT1 (0.98) | DNMT1DNMT3ADNMT3LEHMT1MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | claimed |
| US-20210128600-A1 | Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2021-05-06 | — | — | US | claimed |
| EP-3207932-A1 | DNA METHYLTRANSFERASE INHIBITORS FOR RETT SYNDROME THERAPY | Universität Stuttgart (DE) | 2017-08-23 | — | — | EP | claimed |
| US-20250295686-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. | 2025-09-25 | — | — | US | disclosed |
| US-11992500-B2 | Use of methylation inhibitors for the treatment of autoimmune diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240125787-A1 | STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11874276-B2 | STING levels as a biomarker for cancer immunotherapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| WO-2023069943-A1 | COMBINATION DECITABINE AND MPS1 INHIBITOR THERAPY TO PRIME CANCER IMMUNOGENICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | THE BROAD INSTITUTE, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11092602-B2 | Methods and compositions relating to proteasome inhibitor resistance | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2021-08-17 | — | — | US | disclosed |
| EP-2078008-A2 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SuperGen, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009049132-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049132-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2008046085-A2 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | DNMT1 4323/4885DNMT3A 3754/4885DNMT3L 4078/4885 |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3A 2/4885DNMT3L 3/4885 |
| US-11092602-B2 | Methods and compositions relating to proteasome inhibitor resistance | PSMG3, PSMB1, PSMB11 | DNMT1 2760/4885DNMT3A 3574/4885DNMT3L 2739/4885 |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3A 2/4885DNMT3L 3/4885 |
| US-11564970-B2 | Compositions and methods for combinatorial drug discovery in nanoliter droplets | RAB5IF, LIPA, CLTB | DNMT1 4398/4885DNMT3A 3959/4885DNMT3L 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.